Tukysa 50 mg (Tucatinib TABLET) 50 MG

TUKYSA 50 MG tablets contain tucatinib, a targeted therapy for specific cancer treatments. Learn about its uses, effects, and precautions.

Strength

50 MG

Manufacturer / TM Owner

SEAGEN INC.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TUKYSA 50 MG tablets are used in the treatment of certain types of cancer. Tucatinib, the active ingredient, is often prescribed for advanced or metastatic cancers. Patients may wonder, 'What is TUKYSA used for?' It is typically used in combination with other cancer therapies to target specific proteins involved in cancer cell growth.

Side Effects

Common effects of TUKYSA 50 MG tablets may include fatigue, nausea, and diarrhea. Some patients may experience changes in liver function or heart rhythm. It's important to discuss any persistent or severe side effects with a healthcare provider.

Precautions & Warnings

TUKYSA 50 MG tablets should be handled with care. They are intended for oral use and should be stored as directed. Patients should avoid crushing or breaking the tablets unless instructed. Pregnant women or those planning to become pregnant should consult a healthcare provider before use.

Avoid Interactions

TUKYSA 50 MG tablets may interact with certain medications, including those metabolized by the liver. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements. Alcohol and other substances that affect liver function may also interact with tucatinib.

Frequently Asked Questions

TUKYSA 50 MG tablets are used in the treatment of specific types of cancer, often in combination with other therapies.

TUKYSA 50 MG tablets are taken orally, typically as prescribed by a healthcare provider. They should be swallowed whole with water.

Common side effects may include fatigue, nausea, and diarrhea. Patients should discuss any persistent or severe effects with their healthcare provider.

TUKYSA may interact with certain medications. Patients should inform their healthcare provider about all medications they are taking.

Pregnant women or those planning to become pregnant should consult a healthcare provider before using TUKYSA.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.